Payoneer Global Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Payoneer Global Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.05B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $977.72M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $831.10M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $627.62M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $473.40M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $345.59M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $317.75M | Mar 3, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $813.41M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $710.29M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $590.83M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $563.57M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $460.58M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $339.59M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $300.53M | Mar 3, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.19M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $121.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $93.33M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($11.97M) | Feb 27, 2025 |
| FY2021 | Dec 31, 2021 | ($18.90M) | Mar 3, 2022 |
| FY2021 | Dec 31, 2020 | ($11.22M) | Mar 3, 2022 |
| FY2021 | Dec 31, 2019 | ($625.0K) | Mar 3, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $124.67M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $149.03M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $103.61M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($22.21M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($30.21M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($17.30M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $3.64M | Mar 3, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $155.42M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $134.63M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $119.20M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $115.04M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $80.76M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $52.30M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $34.77M | Mar 3, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $233.49M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $176.93M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $159.49M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $83.96M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $20.02M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $9.53M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($14.31M) | Mar 3, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.87M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $8.19M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $8.46M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $10.50M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $6.89M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $4.99M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $9.15M | Mar 3, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.96B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.93B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $7.28B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.59B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.08B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $3.67B | Mar 3, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.25B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.21B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.62B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.05B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $4.59B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $3.48B | Mar 3, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $704.43M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $724.79M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $664.27M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $545.26M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $487.07M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $24.30M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | ($5.36M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | ($16.46M) | Mar 3, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.79M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $77.79M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $19.89M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $19.89M | Feb 28, 2024 |
| FY2023 | Dec 31, 2021 | $21.13M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $22.54M | Feb 28, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $179.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $105.97M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($15.20M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($108.53M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($94.05M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($60.07M) | Mar 3, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $415.54M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $497.47M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $617.02M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $543.30M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $465.93M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $102.99M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $114.90M | Mar 3, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 3, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 3, 2022 |
| FY2021 | Dec 31, 2019 | 0 | Mar 3, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 3, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 3, 2022 |
| FY2021 | Dec 31, 2019 | 0 | Mar 3, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 348.70M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 360.09M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 357.59M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 352.84M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 340.38M | Feb 28, 2023 |
| FY2023 | Apr 1, 2021 | 49.70M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | 48.61M | Mar 3, 2022 |